PRINCETON, N.J., Nov. 6, 2018 /PRNewswire/ -- NovoPath, Inc. announces that MediPath, LLC (MediPath) has selected the NovoPath™ Anatomic Pathology Software Platform as its LIS for anatomic pathology. As a TopLine MD affiliated center, MediPath Pathology Lab is committed to providing top-of-line service to their clients by constantly sourcing the most innovative solutions that improve patient care.
"We are pleased that MediPath chose NovoPath for its AP platform as it launches its state-of-the-art facility," said Rick Callahan, Vice President of Sales and Marketing for NovoPath. "We look forward to partnering with MediPath to help create workflows that emphasize quality and accuracy and take advantage of the latest technology."
"During the thorough selection process, MediPath had an opportunity to survey the capabilities of several vendors," stated Dr. Sandra Aponte, Medical Director and Lead Pathologist for MediPath. "NovoPath's solution best aligned with MediPath's needs and offered the most robust and flexible capabilities at a competitive price. We felt it was the best choice to help position us to meet today's challenges and to support our future growth plans."
NovoPath continues to partner with lab industry leaders in the healthcare sector to succeed in the ever-changing laboratory environment.
To experience the benefits of NovoPath firsthand, visit www.NovoPath.com and request a complimentary demonstration.
NovoPath, Inc. is a leading U.S.-based Lab Information Systems (LIS) company with over 24 years of experience in serving the Anatomic, Clinical and Molecular Pathology, Genetic Testing and Clinical Trials marketplaces. NovoPath's clients range from national and regional reference labs to University and Teaching Hospitals, Regional and Community Hospitals and Specialty Labs. NovoPath's mission is to provide unique and unparalleled solutions and services to all aspects of the Diagnostic Laboratory sector in a way that improves workflow, reduces the probability of human error, ensures results accuracy for greater patient safety, protects patient confidentiality, and above all, produces more precise and informative diagnostic outcomes.
SOURCE NovoPath, Inc.